Skip to main content

Advertisement

Table 1 General characteristics of preclinical studies investigating the efficacy of stem cells in models of PAH

From: Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies

Author (year) Species, strain, sex No. of controls No. of treated animals PAH model SC source SC route SC dose Timing of SC therapy after PAH Follow-up (weeks)
Lim et al.(2016) [39] Rat, SPF, M 5 5 MCT (60 mg/kg) hBM Tail vein 2.5 × 105 14 days 2 weeks
Lee et al. (2017) [36] Rat, SPD, M 4 6 MCT (60 mg/kg) hUCB Jugular vein 3 × 105 7 days 1 week
3 weeks
4 6
4 4 3 × 105 7 days 1 week
3 weeks
4 4
Guo et al. (2013) [30] Rat, SPD, M 10 10 MCT (60 mg/kg) rBM Jugular vein 5 × 106 21 days 3 weeks
Luan et al.(2012) [42] Rat, SPD, NR 20 20 Surgical operation rBM Sublingual vein 1–5 × 106 28 days 2 weeks
Baber et al. (2006) [25] Rat, SPD, M 10 10 MCT (60 mg/kg) rBM Intratracheal 3 × 106 14 days 3 weeks
Chen et al. (2014) [27] Rat, SPD, NR 7 7 MCT (50 mg/kg) rBM Intravenous 5 × 106 21 days 2 weeks
Chen et al. (2016) [26] Rat, Wistar, M 10 10 MCT (60 mg/kg) rBM Tail vein 1 × 106 14 days 3 weeks
Cheng et al. (2017) [29] Rat, Lewis, M 10 10 MCT (60 mg/kg) rBM Tail vein 3 × 106 21 days 3 weeks
Huang et al.(2016) [31] Rat, SPD, M 6 6 MCT (60 mg/kg) iP Tail vein 2 × 106 14 days 4 weeks
Chen et al.(2016) [28] Rat, SPD, M 8 8 MCT (60 mg/kg) hUCB Caudal vein 1 × 106 5 days 3 weeks
Jiang et al.(2012) [32] Rat, SPD, NR 8 43 MCT (60 mg/kg) rBM Tail vein 4 × 106 3 days 3 weeks
Kang et al. (2015) [33] Rat, SPF, M 10 10 MCT (60 mg/kg) hUCB Tail vein 2.5 × 105 14 days 2 weeks
Kimet al (2012) [34] Rat, SPD, M 6 6 MCT (60 mg/kg) rBM Tail vein 2 × 107 7 days 1 week
6 6 3 weeks
Kim et al. (2016) [35] Rat, SPD, M 6 6 MCT (60 mg/kg) hUCB External jugular vein 3 × 106 7 days 1 week
3 weeks
6 6
8 8
Liang et al. (2015) [38] Rat, SPD, M 10 10 MCT (40 mg/kg) rADM Left external jugular vein 1 × 106 7 days 2 weeks
8 10 3 weeks
Liu et al. (2015) [40] Rat, SPD, F 8 8 MCT (60 mg/kg) hUCB Caudal vein 1 × 106 5 days 3 weeks
Luan et al. (2013) [43] Rat, SPD, M 10 10 MCT (50 mg/kg) rBM Sublingual vein 1 × 107 7 days 23 weeks
Luo et al. (2014) [44] Rat, SPD, M 8 8 MCT (40 mg/kg) rADM Left jugular vein 1 × 106 14 days 1 week
8 8 2 weeks
8 8 3 weeks
Raoul et al. (2007) [45] Mouse, C57BL/6, F 5 5 MCT (5 mg/kg) rBM Tail vein 2.5 × 106 3 days 3 weeks
Rathinasabapathy et al. (2016) [46] Rat, SPD, M 8 8 MCT (50 mg/kg) rADM Jugular vein 1 × 106 14 days 2 weeks
Somanna et al. (2014) [47] Rat, SPD, NR 6 6 MCT (60 mg/kg) hADM Intratracheal 3 × 106 14 days 2 weeks
Zhang et al. (2012) [49] Mouse, ICR, NR 10 10 MCT (400 mg/kg) rBM Tail vein 5 × 105 7 days 2 weeks
Zhang et al. (2012) [50] Rat, SPD, M 9 9 MCT (50 mg/kg) hUCB Sublingual vein 3 × 106 7 days 2 weeks
Umar et al. (2009) [48] Rat, Wistar, F 10 10 MCT (60 mg/kg) rBM Jugular vein 1 × 106 14 days 2 weeks
10 10 3 weeks
10 10 4 weeks
Liu et al. (2011) [41] Rat, Wistar, M 17 16 Surgical operation rADM Right jugular vein 5 × 107 84 days 2 weeks
Takemiya et al. (2009) [15] Rat, Lewis, M 10 10 MCT (60 mg/kg) rBM Tail vein 5 × 105 14 days 2 weeks
Horimoto et al. (2005) [14] Rat, SPD, M 10 10 MCT (60 mg/kg) rBM Right femoral vein 1 × 106 7 days 2 weeks
Lee et al. (2015) [37] Rat, SPD, M 8 8 MCT (60 mg/kg) hUCB External jugular vein 3 × 106 7 days 1 week
8 8 2 weeks
8 8 3 weeks
  1. PAH pulmonary arterial hypertension, SPF specific-pathogen-free, SPD Sprague Dawley, M male, F female, NR not reported, SCs stem cells, hBM human bone marrow mesenchymal tissue, hUCB human umbilical cord blood-derived mesenchymal tissue, rBM rat bone marrow mesenchymal tissue, iP murine-induced pluripotent stem cells, BM bone marrow mesenchymal tissue, rADM rat adipose-derived stromal tissue, ADM adipose-derived stromal tissue
  2. Follow-up (weeks) indicates the observation time of outcomes after stem cell administration